Mesupron is a first-in-class, orally-administered protease inhibitor; high levels of certain proteases have been associated with poor prognosis for various solid tumor cancers. The drug represents a non-cytotoxic approach to cancer therapy with several potential mechanism of action to inhibit tumor invasion and metastasis. Read more . . .
The Food and Drug Administration (FDA) has granted orphan drug designation to Mesupron (RedHill Biopharma) for the adjuvant treatment of pancreatic cancer.